Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432
复制标题
DOI：
10.1016/j.vaccine.2009.09.018
复制
发表时间：
2009-11-16
期刊：
影响因子：
5.5
通讯作者：
Kageyama, Shinichi
中科院分区：
文献类型：
--
作者：
Aoki, Masatoshi;Ueda, Shugo;Kageyama, Shinichi
将NY-ESC-1蛋白与胆固醇普鲁兰多糖（CHP）复合的组合疫苗CHP-NY-ESO-1和截短的146 HER 2蛋白与CHP的组合疫苗CHP-HER 2与免疫佐剂OK-432皮下施用至8名食管癌患者。接种耐受性良好。使用来自先前单一CHP-NY-ESO-1或CHP-HER 2疫苗试验的患者血清和样品分析NY-ESO-1和HER 2特异性抗体应答。联合疫苗研究中对NY-ESO-1的应答与单一疫苗相当。对于对HER 2的应答，联合疫苗中的抗体应答较少。尽管对NY-ESO-1和HER 2抗原的抗体应答存在显著的个体差异，但每例患者对这些抗原的反应模式相当。OK-432的抗体没有增加。靶向多种抗原的蛋白质癌症疫苗是可行的。(C)2009爱思唯尔有限公司版权所有。
Combination vaccines of the NY-ESC-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible. (C) 2009 Elsevier Ltd. All rights reserved.